These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24743480)

  • 1. [Effectiveness of tolvaptan for postoperative heart failure in a patient with combined valvular disease and pulmonary hypertension].
    Kondo T; Hoshino J; Fukada Y; Hirota M; Takahashi Y; Isomura T
    Kyobu Geka; 2014 Feb; 67(2):117-20. PubMed ID: 24743480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study.
    Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
    Am J Nephrol; 2017; 46(5):417-426. PubMed ID: 29130954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension.
    Tamura Y; Kimura M; Takei M; Ono T; Kuwana M; Satoh T; Fukuda K; Humbert M
    Eur Respir J; 2015 Jul; 46(1):283-6. PubMed ID: 25929949
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of tolvaptan on congestive heart failure complicated with chylothorax in a neonate.
    Sato N; Sugiura T; Nagasaki R; Suzuki K; Ito K; Kato T; Inukai S; Saitoh S
    Pediatr Int; 2015 Oct; 57(5):1020-2. PubMed ID: 26508187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
    Onogawa T; Sakamoto Y; Nakamura S; Nakayama S; Fujiki H; Yamamura Y
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S67-76. PubMed ID: 22120095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia.
    Ramamohan V; Mladsi D; Ronquest N; Kamat S; Boklage S
    Hosp Pract (1995); 2017 Aug; 45(3):111-117. PubMed ID: 28449624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Tolvaptan in Patients with Volume Overload after Cardiac Surgery.
    Noguchi K; Tanaka M; Katayama I; Yamabe T; Yuji D; Oosiro N; Sirouzu M
    Heart Surg Forum; 2015 Nov; 18(6):E232-6. PubMed ID: 26726710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful Treatment of Severe Right-Sided Heart Failure Due to Postoperative Constrictive Pericarditis With Tolvaptan.
    Kanaya M; Matsushita K; Inami T; Yamasaki S; Mizumi S; Minamishima T; Goda A; Ueda A; Sakata K; Satoh T; Yoshino H
    Am J Ther; 2016; 23(1):e264-7. PubMed ID: 25343308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia].
    Li L; Bai H; Zhu WL;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):936-40. PubMed ID: 22321279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects and safety of oral tolvaptan in patients with congestive heart failure: A systematic review and network meta-analysis.
    Wu MY; Chen TT; Chen YC; Tarng DC; Wu YC; Lin HH; Tu YK
    PLoS One; 2017; 12(9):e0184380. PubMed ID: 28898297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey.
    Sağ S; Aydın Kaderli A; Yıldız A; Gül BC; Özdemir B; Baran İ; Güllülü S; Aydınlar A; Çavuşoğlu Y
    Turk Kardiyol Dern Ars; 2017 Jul; 45(5):415-425. PubMed ID: 28694395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure.
    Felker GM; Mentz RJ; Cole RT; Adams KF; Egnaczyk GF; Fiuzat M; Patel CB; Echols M; Khouri MG; Tauras JM; Gupta D; Monds P; Roberts R; O'Connor CM
    J Am Coll Cardiol; 2017 Mar; 69(11):1399-1406. PubMed ID: 27654854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amiodarone-Induced Hyponatremia Masked by Tolvaptan in a Patient with an Implantable Left Ventricular Assist Device.
    Nakamura M; Sunagawa O; Kugai T; Kinugawa K
    Int Heart J; 2017 Dec; 58(6):1004-1007. PubMed ID: 29151494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload.
    Konstam MA; Kiernan M; Chandler A; Dhingra R; Mody FV; Eisen H; Haught WH; Wagoner L; Gupta D; Patten R; Gordon P; Korr K; Fileccia R; Pressler SJ; Gregory D; Wedge P; Dowling D; Romeling M; Konstam JM; Massaro JM; Udelson JE;
    J Am Coll Cardiol; 2017 Mar; 69(11):1409-1419. PubMed ID: 28302292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictability of tricuspid annular plane systolic excursion for the effectiveness of tolvaptan in patients with heart failure.
    Niwa T; Waseda K; Mizuno T; Nakano Y; Mukai K; Wakabayashi H; Watanabe A; Ando H; Takashima H; Amano T
    J Echocardiogr; 2017 Sep; 15(3):118-126. PubMed ID: 28194742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
    Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
    Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of Tolvaptan for the Postoperative Control After Kidney Transplantation in a Patient With Cardiac Hypofunction: A Case Report.
    Akabane M; Ishii Y; Nakamura Y; Yokoyama T; Miki K
    Transplant Proc; 2021 May; 53(4):1288-1291. PubMed ID: 33865611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute Renal Injury Induced by Hypersensitivity to Tolvaptan in an Elderly Patient with Congestive Heart Failure.
    Yamaguchi M; Nishihira K; Okubo T; Asada Y; Kitamura K
    Intern Med; 2015; 54(10):1243-6. PubMed ID: 25986264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials.
    Felker GM; Mentz RJ; Adams KF; Cole RT; Egnaczyk GF; Patel CB; Fiuzat M; Gregory D; Wedge P; O'Connor CM; Udelson JE; Konstam MA
    Circ Heart Fail; 2015 Sep; 8(5):997-1005. PubMed ID: 26374918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response Prediction and Influence of Tolvaptan in Chronic Heart Failure Patients Considering the Interaction of the Renin-Angiotensin-Aldosterone System and Arginine Vasopressin.
    Kadota M; Ise T; Yagi S; Iwase T; Akaike M; Ueno R; Kawabata Y; Hara T; Ogasawara K; Bando M; Bando S; Matsuura T; Yamaguchi K; Yamada H; Soeki T; Wakatsuki T; Sata M
    Int Heart J; 2016 Jul; 57(4):461-5. PubMed ID: 27357439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.